Daiichi Sankyo (DSNKY) News Today $24.40 -0.15 (-0.61%) As of 08/8/2025 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestBuy This Stock DSNKY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Daiichi Sankyo (OTCMKTS:DSNKY) Trading Up 0.6% - Time to Buy?August 5, 2025 | marketbeat.comDaiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down - Should You Sell?July 22, 2025 | marketbeat.comDaiichi Sankyo Co. Ltd. ADR (DSNKY) Stock Price Today - WSJJuly 18, 2025 | wsj.comDaiichi Sankyo (OTCMKTS:DSNKY) Trading Up 0.6% - Here's What HappenedJuly 12, 2025 | marketbeat.comDaiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down - Time to Sell?July 2, 2025 | marketbeat.comDaiichi Sankyo Co Ltd ADR News (DSNKY) - Investing.comJune 26, 2025 | investing.comDaiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down - Here's WhyJune 26, 2025 | marketbeat.comFDA Approves AstraZeneca And Daiichi Sankyo's Datroway For Type Of Lung CancerJune 24, 2025 | benzinga.comDaiichi Sankyo (OTCMKTS:DSNKY) Trading Down 0.1% - Should You Sell?June 20, 2025 | marketbeat.comDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Short Interest UpdateJune 13, 2025 | marketbeat.comDaiichi Sankyo, AstraZeneca Announce Promising DATROWAY Combination Data in NSCLCJune 2, 2025 | msn.comDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Significant Decrease in Short InterestMay 30, 2025 | marketbeat.comMerck, Daiichi Sankyo pull marketing application for lung cancer therapyMay 29, 2025 | msn.comDaiichi Sankyo Continues to Transform Treatment Landscape for Patients with Cancer with Practice-Changing Data at ASCOMay 22, 2025 | businesswire.comDaiichi Sankyo (OTCMKTS:DSNKY) Stock Price Up 0.9% - Should You Buy?May 16, 2025 | marketbeat.comShort Interest in Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Grows By 6,475.0%April 16, 2025 | marketbeat.comWayfinder Biosciences and Daiichi Sankyo collaborate to develop novel RNA-targeting therapies for neurodegenerative diseaseApril 15, 2025 | tmcnet.comDaiichi Sankyo: Good Diversification Tool For U.S. InvestorsApril 11, 2025 | seekingalpha.comDaiichi Sankyo (OTCMKTS:DSNKY) Sets New 1-Year Low - Time to Sell?April 10, 2025 | marketbeat.comDESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric CancerMarch 31, 2025 | finance.yahoo.comDSKYF Daiichi Sankyo Company, LimitedMarch 21, 2025 | seekingalpha.comShort Interest in Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Drops By 50.0%March 15, 2025 | marketbeat.comDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Large Drop in Short InterestFebruary 28, 2025 | marketbeat.comDaiichi Sankyo (OTCMKTS:DSNKY) Hits New 1-Year Low - Here's What HappenedFebruary 25, 2025 | marketbeat.comDaiichi Sankyo (OTCMKTS:DSNKY) Hits New 52-Week Low - What's Next?February 20, 2025 | marketbeat.comDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Significant Increase in Short InterestFebruary 14, 2025 | marketbeat.comDaiichi Sankyo (OTCMKTS:DSNKY) Hits New 1-Year Low - Should You Sell?February 12, 2025 | marketbeat.comDaiichi Sankyo (OTCMKTS:DSNKY) Hits New 12-Month Low - What's Next?February 10, 2025 | marketbeat.comDaiichi Sankyo (OTCMKTS:DSNKY) Announces Quarterly Earnings ResultsJanuary 31, 2025 | marketbeat.comDaiichi Sankyo (OTCMKTS:DSNKY) Updates FY 2024 Earnings GuidanceJanuary 31, 2025 | marketbeat.comDaiichi Sankyo Appoints Hiroyuki Okuzawa To Succeed Sunao Manabe As CEOJanuary 31, 2025 | markets.businessinsider.comDaiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive OfficerJanuary 30, 2025 | businesswire.comFDA Approves AstraZeneca And Daiichi Sankyo's ENHERTU For HER2-Low/Ultralow Breast CancerJanuary 27, 2025 | markets.businessinsider.comDaiichi Sankyo’s Growth Prospects Bolstered by FDA Approval of Dato-DXd and Upcoming CatalystsJanuary 24, 2025 | markets.businessinsider.comDaiichi Sankyo Shares Jump After U.S. FDA Approves Breast Cancer DrugJanuary 20, 2025 | marketwatch.comFDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast CancerJanuary 18, 2025 | markets.businessinsider.comDaiichi Sankyo buys solid tumour ADC from Glycotope for $132.5mJanuary 15, 2025 | msn.comDaiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbHJanuary 13, 2025 | uk.finance.yahoo.comDaiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Significant Growth in Short InterestJanuary 13, 2025 | marketbeat.comDatopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung CancerJanuary 13, 2025 | finance.yahoo.comHigh Expectations And Data Disappointments Have Driven Daiichi Sankyo LowerJanuary 10, 2025 | seekingalpha.comDaiichi Sankyo gets Japanese approval for DatrowayDecember 28, 2024 | msn.comAstraZeneca, Daiichi Sankyo have voluntarily withdrawn a Dato-DXd MAA in EUDecember 24, 2024 | markets.businessinsider.comAstraZeneca, Daiichi Sankyo Withdraw Authorization Application for Lung Cancer Treatment in EUDecember 24, 2024 | marketwatch.comAstraZeneca And Daiichi Sankyo Withdraw EU Marketing Application For Datopotamab DeruxtecanDecember 24, 2024 | markets.businessinsider.comDaiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third timeNovember 20, 2024 | msn.comDaiichi Sankyo’s Strategic Advancements and Innovative ADC Developments Drive Buy RatingNovember 13, 2024 | markets.businessinsider.comDaiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOSNovember 13, 2024 | finance.yahoo.comAstraZeneca, Daiichi Sankyo sumbit new BLA for datopotamab deruxtecanNovember 12, 2024 | markets.businessinsider.comAlteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ TechnologyNovember 10, 2024 | finance.yahoo.com Get Daiichi Sankyo News Delivered to You Automatically Sign up to receive the latest news and ratings for DSNKY and its competitors with MarketBeat's FREE daily newsletter. Email Address DSNKY Media Mentions By Week DSNKY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DSNKY News Sentiment▼0.000.45▲Average Medical News Sentiment DSNKY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DSNKY Articles This Week▼11▲DSNKY Articles Average Week Get Daiichi Sankyo News Delivered to You Automatically Sign up to receive the latest news and ratings for DSNKY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sanofi News Today GSK News Today Takeda Pharmaceutical News Today argenex News Today BeOne Medicines News Today BioNTech News Today Summit Therapeutics News Today Insmed News Today Teva Pharmaceutical Industries News Today Genmab A/S News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:DSNKY) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daiichi Sankyo Co., Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Daiichi Sankyo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
